ReviewJournal of clinical and translational hepatology2019
Fatty Liver Disease and Gut Microbiota: A Comprehensive Update.
Review in Journal of clinical and translational hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Gut microbiota composition combined with reduced intestinal fatty acid uptake prevents hepatic steatosis in obesity-resistant mice fed a high-fat diet.Scientific reports · 2025Article
- Adipokine and Hepatokines in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Current and Developing Trends.Biomedicines · 2025Article
- Review of nonpharmacological interventions for delaying the effects of cerebral neuropathy caused by diabetes.Frontiers in endocrinology · 2025Review
- Dysbiosis of gut microbiota in C57BL/6-Lepem1hwl/Korl mice during microplastics-caused hepatic metabolism disruption.PloS one · 2025Article
- Metabolic dysfunction-associated steatotic liver disease-induced changes in the antioxidant system: a review.Archives of toxicology · 2025Review
- A Scoping Review on Hepatoprotective Mechanism of Herbal Preparations through Gut Microbiota Modulation.Current issues in molecular biology · 2024Article
- Vinpocetine and Lactobacillus improve fatty liver in rats: role of adiponectin and gut microbiome.AMB Express · 2024Article
- Dysregulated bile acid homeostasis: unveiling its role in metabolic diseases.Medical review (2021) · 2024Review
- Low-Iron Diet-Induced Fatty Liver Development Is Microbiota Dependent and Exacerbated by Loss of the Mitochondrial Iron Importer Mitoferrin2.Nutrients · 2024Article
- Dyslipidemia, Cholangitis and Fatty Liver Disease: The Close Underexplored Relationship: A Narrative Review.Journal of clinical medicine · 2024Review
- Impacts of pancreatic exocrine insufficiency on gut microbiota.Journal of Zhejiang University. Science. B · 2024Article
- Gut Microbiota Patterns in Patients with Non-Alcoholic Fatty Liver Disease: A Comprehensive Assessment Using Three Analysis Methods.International journal of molecular sciences · 2023Article
- New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk.Nutrients · 2023Review
- Therapeutic mechanisms of the medicine and food homology formula Xiao-Ke-Yin on glucolipid metabolic dysfunction revealed by transcriptomics, metabolomics and microbiomics in mice.Chinese medicine · 2023Article
- Microbiome-liver crosstalk: A multihit therapeutic target for liver disease.World journal of gastroenterology · 2023Review
- Antibiotic-Therapy-Induced Gut Dysbiosis Affecting Gut Microbiota-Brain Axis and Cognition: Restoration by Intake of Probiotics and Synbiotics.International journal of molecular sciences · 2023Review
- Association between gut microbiota and NAFLD/NASH: a bidirectional two-sample Mendelian randomization study.Frontiers in cellular and infection microbiology · 2023Article
- Unlocking the Potential of the Human Microbiome for Identifying Disease Diagnostic Biomarkers.Diagnostics (Basel, Switzerland) · 2022Review
- Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome.International journal of molecular sciences · 2022Article
- Odd chain fatty acid metabolism in mice after a high fat diet.The international journal of biochemistry & cell biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the accumulation of fat in the liver in the absence of secondary causes. NAFLD is a multifactorial disease that results from the interaction of genetic predisposition and metabolic, inflammatory and environmental factors. Among these factors, dysregulation of gut microbiome has been linked to the development of fatty liver disease. The microbiome composition can be modified by dietary habits leading to gut microbiome dysbiosis, especially when a diet is rich in saturated fats, animal products and fructose sugars. Different species of bacteria in the gut metabolize nutrients differently, triggering different pathways that contribute to the accumulation of fat within the liver and triggering inflammatory cascades that promote liver damage. In this review, we summarize the current understanding of the roles of gut microbiota in mediating NAFLD development and discuss possible gut microbiota-targeted therapies for NAFLD. We summarize experimental and clinical evidence, and draw conclusions on the therapeutic potential of manipulating gut microbiota to decrease the incidence and prevalence of fatty liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.